White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network
Top Cited Papers
- 26 March 2016
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 79 (6), 929-939
- https://doi.org/10.1002/ana.24647
Abstract
Objective White matter hyperintensities (WMHs) are areas of increased signal on T2‐weighted magnetic resonance imaging (MRI) scans that most commonly reflect small vessel cerebrovascular disease. Increased WMH volume is associated with risk and progression of Alzheimer's disease (AD). These observations are typically interpreted as evidence that vascular abnormalities play an additive, independent role contributing to symptom presentation, but not core features of AD. We examined the severity and distribution of WMH in presymptomatic PSEN1, PSEN2, and APP mutation carriers to determine the extent to which WMH manifest in individuals genetically determined to develop AD. Methods The study comprised participants (n = 299; age = 39.03 ± 10.13) from the Dominantly Inherited Alzheimer Network, including 184 (61.5%) with a mutation that results in AD and 115 (38.5%) first‐degree relatives who were noncarrier controls. We calculated the estimated years from expected symptom onset (EYO) by subtracting the affected parent's symptom onset age from the participant's age. Baseline MRI data were analyzed for total and regional WMH. Mixed‐effects piece‐wise linear regression was used to examine WMH differences between carriers and noncarriers with respect to EYO. Results Mutation carriers had greater total WMH volumes, which appeared to increase approximately 6 years before expected symptom onset. Effects were most prominent for the parietal and occipital lobe, which showed divergent effects as early as 22 years before estimated onset. Interpretation Autosomal‐dominant AD is associated with increased WMH well before expected symptom onset. The findings suggest the possibility that WMHs are a core feature of AD, a potential therapeutic target, and a factor that should be integrated into pathogenic models of the disease. Ann Neurol 2016;79:929–939Keywords
Funding Information
- NIH/NIA (U19 AG032438, AG051348)
- NIHR Queen Square Dementia BRU
- German Center for Neurodegenerative Diseases (DZNE)
- Brain Exit Foundation Fellowship
This publication has 51 references indexed in Scilit:
- Neuropathologic basis of white matter hyperintensity accumulation with advanced ageNeurology, 2013
- White matter hyperintensities predict amyloid increase in Alzheimer's diseaseNeurobiology of Aging, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseThe New England Journal of Medicine, 2012
- Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disordersNature Reviews Neuroscience, 2011
- Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's diseaseBrain Research, 2011
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008
- MR‐based hippocampal volumetry in the diagnosis of Alzheimer's diseaseNeurology, 1992
- Alternative Transformations to Handle Extreme Values of the Dependent VariableJournal of the American Statistical Association, 1988
- Robust Locally Weighted Regression and Smoothing ScatterplotsJournal of the American Statistical Association, 1979
- Piecewise RegressionJournal of the American Statistical Association, 1970